Tromethamine
- Generic Name
- Tromethamine
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11NO3
- CAS Number
- 77-86-1
- Unique Ingredient Identifier
- 023C2WHX2V
- Background
An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)
- Indication
For the prevention and correction of metabolic acidosis.
- Associated Conditions
- Metabolic Acidosis
Cognito Therapeutics Showcases Early-Stage Cost-Effectiveness of Spectris Therapy for Alzheimer’s Disease
Cognito Therapeutics presented an early-stage cost-effectiveness analysis of its Spectris therapy for Alzheimer’s disease at the ISPOR Europe 2024 Annual Meeting, highlighting its potential to reduce patient costs and alleviate the financial burden on healthcare systems.
Spectris Shows Promise in Reducing Alzheimer's Disease Dependence in Phase 2 Trial
• Spectris, a novel treatment by Cognito Therapeutics, significantly reduced the Alzheimer's Disease Dependence Score (DS) compared to sham treatment over 18 months.
• The OVERTURE I/II study demonstrated high tolerability and adherence to Spectris, with no serious treatment-related adverse events observed in participants.
• The trial data indicated remarkable preservation of brain structures and daily functions, particularly in the corpus callosum, offering new hope for Alzheimer's treatment.
• Cognito Therapeutics is further investigating Spectris in the ongoing phase 3 HOPE pivotal trial for patients with mild-to-moderate Alzheimer's disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath